Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: Implications for genetic counseling

Journal of the American Academy of Dermatology

Volumn 71, Issue 5, 2014, Pages 888-895

  Potrony, Miriam ^a,c   Puig Butillé, Joan Anton ^a,b   Aguilera, Paula ^a,c   Badenas, Celia ^a,b   Carrera, Cristina ^a,c   Malvehy, Josep ^a,c   Puig, Susana ^a,c  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b Biochemical and Molecular Genetics Service   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Breast cancer; CDKN2A; Genetic counseling; Lung cancer; Melanoma; Pancreatic cancer; Prevention; Risk; Smoking

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GENOMIC DNA;

ADULT; BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; CROSS-SECTIONAL STUDY; FAMILY HISTORY; GENETIC COUNSELING; GERMLINE MUTATION; HIGH RISK PATIENT; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; MIDDLE AGED; MUTATIONAL ANALYSIS; ONSET AGE; PANCREAS CANCER; PEDIGREE; PRIORITY JOURNAL; SPANIARD; AGED; BREAST NEOPLASMS; GENETIC PREDISPOSITION; GENETICS; LUNG NEOPLASMS; PANCREATIC NEOPLASMS; PREVALENCE; RISK FACTOR; SKIN NEOPLASMS; SPAIN;

ADULT; AGE OF ONSET; AGED; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MELANOMA; MIDDLE AGED; PANCREATIC NEOPLASMS; PREVALENCE; RISK FACTORS; SKIN NEOPLASMS; SPAIN;

EID: 84927571470     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.06.036     Document Type: Conference Paper

References (41)

1. Whiteman DC, Green AC. Melanoma and sun exposure: where are we now? Int J Dermatol 1999;38:481-9.
2. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma, I: common and atypical nevi. Eur J Cancer 2005;41:28-44.
3. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, et al. Meta-analysis of risk factors for cutaneous melanoma, III: family history, actinic damage and phenotypic factors. Eur J Cancer 2005;41:2040-59.
4. Florell SR, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G, et al. Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol 2005;23:7168-77.
5. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007;44:99-106.
6. Nelson AA, Tsao H. Melanoma and genetics. Clin Dermatol 2009;27:46-52.
7. Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M, et al. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet 2013;50:264-70.
8. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006;66:9818-28.
9. Vasen HF, Gruis NA, Frants RR, Van Der Velden PA, Hille ET, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000;87:809-11.
10. Mukherjee B, Delancey JO, Raskin L, Everett J, Jeter J, Begg CB, et al. Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers. J Natl Cancer Inst 2012;104:953-6.
11. Ghiorzo P, Ciotti P, Mantelli M, Heouaine A, Queirolo P, Rainero ML, et al. Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 1999;83:441-8.
12. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000;92:1260-6.
13. Puig S, Ruiz A, Castel T, Volpini V, Malvehy J, Cardellach F, et al. Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene. Hum Genet 1997;101:359-64.
14. Badenas C, Aguilera P, Puig-Butille JA, Carrera C, Malvehy J, Puig S. Genetic counseling in melanoma. Dermatol Ther 2012;25:397-402.
15. Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 2009;61:677.e1-14.
16. Ribes J, Esteban L, Cleries R, Galceran J, Marcos-Gragera R, Gispert R, et al. Cancer incidence and mortality projections up to 2020 in Catalonia by means of Bayesian models. Clin Transl Oncol doi:10.1007/s12094-013-1140-z. Published online December 12, 2013.
17. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
18. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, et al. A novel p16INK4A transcript. Cancer Res 1995;55:2995-7.
19. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France; the French familial melanoma study group. Hum Mol Genet 1998;7:209-16.
20. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet 2013: Chapter 7:Unit7.20.
21. Rizos H, Puig S, Badenas C, Malvehy J, Darmanian AP, Jimenez L, et al. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 2001;20:5543-7.
22. Eliason MJ, Larson AA, Florell SR, Zone JJ, Cannon-Albright LA, Samlowski WE, et al. Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol 2006;126:660-6.
23. Ruiz A, Puig S, Malvehy J, Lazaro C, Lynch M, Gimenez-Arnau AM, et al. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. J Med Genet 1999;36:490-3.
24. Walker GJ, Hussussian CJ, Flores JF, Glendening JM, Haluska FG, Dracopoli NC, et al. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 1995;4:1845-52.
25. Cabanillas R, Astudillo A, Valle M, De La Rosa J, Alvarez R, Duran NS, et al. Novel germline CDKN2A mutation associated with head and neck squamous cell carcinomas and melanomas. Head Neck 2013;35:E80-4.
26. Della Torre G, Pasini B, Frigerio S, Donghi R, Rovini D, Delia D, et al. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Br J Cancer 2001;85:836-44.
27. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
28. Ghiorzo P, Fornarini G, Sciallero S, Battistuzzi L, Belli F, Bernard L, et al. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. J Med Genet 2012;49:164-70.
29. Larre Borges A, Cuellar F, Puig-Butille JA, Scarone M, Delgado L, Badenas C, et al. CDKN2A mutations in melanoma families from Uruguay. Br J Dermatol 2009;161:536-41.
30. Nikolaou V, Kang X, Stratigos A, Gogas H, Latorre MC, Gabree M, et al. Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma. Br J Dermatol 2011;165:1219-22.
31. Puig S, Malvehy J, Badenas C, Ruiz A, Jimenez D, Cuellar F, et al. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 2005;23:3043-51.
32. Yang G, Rajadurai A, Tsao H. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J Invest Dermatol 2005;125:1242-51.
33. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 2004;23:5968-77.
34. Maubec E, Chaudru V, Mohamdi H, Blondel C, Margaritte-Jeannin P, Forget S, et al. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family. J Am Acad Dermatol 2012;67:1257-64.
35. Auroy S, Avril MF, Chompret A, Pham D, Goldstein AM, Bianchi-Scarra G, et al. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer 2001;32:195-202.
36. Pastorino L, Bonelli L, Ghiorzo P, Queirolo P, Battistuzzi L, Balleari E, et al. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma. Pigment Cell Melanoma Res 2008;21:700-9.
37. Pedace L, De Simone P, Castori M, Sperduti I, Silipo V, Eibenschutz L, et al. Clinical features predicting identification of CDKN2A mutations in Italian patients with familial cutaneous melanoma. Cancer Epidemiol 2011;35:e116-20.
38. De Snoo FA, Bishop DT, Bergman W, Van Leeuwen I, Van Der Drift C, Van Nieuwpoort FA, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 2008;14:7151-7.
39. Siemiatycki J, Krewski D, Franco E, Kaiserman M. Associations between cigarette smoking and each of 21 types of cancer: a multi-site case-control study. Int J Epidemiol 1995;24:504-14.
40. Gaudet MM, Gapstur SM, Sun J, Diver WR, Hannan LM, Thun MJ. Active smoking and breast cancer risk: original cohort data and meta-analysis. J Natl Cancer Inst 2013;105:515-25.
41. McWilliams RR, Wieben ED, Rabe KG, Pedersen KS, Wu Y, Sicotte H, et al. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet 2011;19:472-8.